
    
      This is a multicenter, open-label, single-arm phase 4 study in patients with plaque psoriasis
      who are etanercept-na√Øve and who are not receiving methotrexate therapy. The study will
      consist of a screening period of up to 30 days, a 24-week treatment period and a 30-day
      follow-up period for safety. Etanercept dosing will follow the recommended label dosing for
      patients with plaque psoriasis.
    
  